MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Molecular Interventions 5:154-157, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.3.4
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simmons, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simmons, M. A.

Viewpoint

Functional Selectivity, Ligand-Directed Trafficking, Conformation-Specific Agonism: What’s In A Name?

Mark A. Simmons

Department of Physiology and Pharmacology, Northeastern Ohio Universities College of Medicine (NEOUCOM), Rootstown, OH 44272-0095

SUMMARY

Research on the design of compounds to selectively affect specific subsets of signals downstream of receptors has burgeoned lately, and several reports discussed at Experimental Biology 2005 indicate progress is being made in the understanding of what makes a drug functionally selective. Different conformations adopted by receptors after associating with specific ligands can determine which intracellular signaling pathways get activated and which do not. The appeal of such specific compounds is enormous when one considers that many disease states might require the subtle manipulation of some (or even one) but not all downstream events stemming from specific receptor activation. Additionally, a better understanding of functional selectivity would likely improve the drug delivery process: if compounds are screened through several functional assays appropriately designed to look for compounds exhibiting a high degree of selectivity, then many potential lead compounds might not be as frequently overlooked.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Simmons
Functional Selectivity of NK1 Receptor Signaling: Peptide Agonists Can Preferentially Produce Receptor Activation or Desensitization
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 907 - 913.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.